Valuation: ALLOVIRPAR

Market Cap 4.92Cr 4.3Cr 3.98Cr 3.65Cr 6.91Cr 474.2Cr 7.03Cr 47Cr 19Cr 231.56Cr 18Cr 18Cr 799.46Cr P/E 2023
-0.37x
P/E 2024 -0.82x
Enterprise Value -6.91Cr -6.04Cr -5.58Cr -5.12Cr -9.7Cr -665.63Cr -9.87Cr -67Cr -26Cr -325.05Cr -26Cr -25Cr -1.12TCr EV / Sales 2023
-
EV / Sales 2024 -
Free-Float
-
Yield 2023 *
-
Yield 2024 -
1 day-4.36%
Current month-53.01%
Current year-53.01%
3 years 4.42
Extreme 4.42
87.17
5 years 4.42
Extreme 4.42
607.43
10 years 4.42
Extreme 4.42
1,126.08

Financials

2023 2024
Net sales - -
Net income -19Cr -17Cr -15Cr -14Cr -27Cr -1.83TCr -27Cr -183.57Cr -72Cr -896.02Cr -72Cr -70Cr -3.09TCr -5.88Cr -5.14Cr -4.75Cr -4.36Cr -8.25Cr -566.29Cr -8.39Cr -57Cr -22Cr -276.54Cr -22Cr -22Cr -954.73Cr
Net Debt -16Cr -14Cr -13Cr -12Cr -22Cr -1.51TCr -22Cr -150.89Cr -59Cr -736.48Cr -59Cr -57Cr -2.54TCr -12Cr -10Cr -9.56Cr -8.77Cr -17Cr -1.14TCr -17Cr -114.04Cr -45Cr -556.61Cr -44Cr -43Cr -1.92TCr
Logo ALLOVIRPAR
AlloVir, Inc. is an allogeneic T cell immunotherapy company with a focus on restoring natural immunity against life-threatening viral diseases in pediatric and adult patients with weakened immune systems. The company’s proprietary technology platforms leverage off-the-shelf, allogeneic, single- and multi-virus-specific T cells for patients with T cell deficiencies who are at risk from the life-threatening consequences of viral diseases. Its technology and manufacturing process enable the potential for the treatment and prevention of a spectrum of devastating viruses with each single allogeneic cell therapy. Its lead product candidate, posoleucel, is a multi-VST therapy that targets six viruses: adenovirus (BKV), cytomegalovirus (EBV), human herpesvirus 6 (HHV-6) and JC virus (JCV). Its proprietary VST manufacturing platform enables the rapid, robust and reproducible generation of single-virus and multi-virus specific cell therapeutic candidates for clinical use.
Employees
6
Sector
-
Date Price Change Volume
17/26/17 $4.610 -4.36% 61,346
15/26/15 $4.820 +5.93% 74,362
14/26/14 $4.550 +2.94% 35,441
13/26/13 $4.420 -0.45% 68,023
10/26/10 $4.440 -1.11% 10,280
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BB
  1. Stock Market
  2. Stocks
  3. ALVR Stock